Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotechnology pioneer using machine learning and automated experiments to transform drug discovery. This page serves as the definitive source for all official company announcements and verified news coverage.
Investors and industry professionals will find timely updates including clinical trial developments, strategic partnerships, and financial results. Our curated collection features press releases on therapeutic advancements, regulatory milestones, and technology innovations from Recursion's proprietary platform.
Key content categories include quarterly earnings reports, research collaborations, pipeline updates, and executive leadership announcements. All materials are sourced directly from company filings and reputable financial news outlets to ensure accuracy.
Bookmark this page for streamlined access to RXRX's latest progress in decoding complex diseases through computational biology. Check regularly for real-time updates on one of biotech's most technologically advanced drug discovery efforts.
Recursion (NASDAQ: RXRX) has dosed the first patient in its Phase 2 clinical trial of REC-3964, an oral, non-antibiotic small molecule designed for recurrent Clostridioides difficile (C. diff) infection. The novel treatment selectively inhibits the glucosyltransferase activity of toxin B produced by C. diff, aiming to prevent recurrence while sparing the gut microbiome. C. diff infections cause significant morbidity and mortality, with up to 175,000 recurrent cases annually in the U.S. and high recurrence rates post-antibiotic treatment. Preclinical studies showed REC-3964's superiority over bezlotoxumab, and Phase 1 trials demonstrated its safety and tolerability. The Phase 2 ALDER trial will enroll around 80 participants across the U.S. and Europe to assess safety, tolerability, pharmacokinetics, and efficacy.
Recursion (NASDAQ: RXRX) has received FDA clearance for an Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader targeting biomarker-enriched solid tumors and lymphoma. This program, developed using Recursion's AI-enabled active learning modules, progressed from target identification to IND-enabling studies in under 18 months.
The company plans to initiate a Phase 1/2 clinical trial in Q4 2024, evaluating REC-1245 in a biomarker-enriched patient population. Recursion identified RBM39's novel regulatory role associated with CDK12 using its maps of biology. The company estimates the initially addressable population for this potential therapeutic to be over 100,000 patients in the US and EU5.
Preclinical data suggest that RBM39 degradation induces splicing defects, downregulating DNA Damage Response networks and cell cycle checkpoints. The upcoming clinical trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245.
Recursion (NASDAQ: RXRX) announced positive top-line results from its SYCAMORE trial, a Phase 2 study of REC-994 for symptomatic Cerebral Cavernous Malformation (CCM). The trial met its primary endpoint of safety and tolerability, with similar profiles across placebo and both 200mg and 400mg dosage arms. Encouraging trends in MRI-based secondary efficacy endpoints were observed, particularly at the highest dose (400mg), showing reduced lesion volume and hemosiderin ring size compared to placebo.
The company plans to advance REC-994's development for potential CCM treatment in subsequent studies. A meeting with the FDA is anticipated to discuss plans for an additional clinical study. Recursion aims to present the data at a future medical conference and submit it for peer-reviewed publication.
Recursion (Nasdaq: RXRX) issued a correction to its earlier press release regarding its second quarter 2024 financial results. The company clarified that its earnings call took place earlier in the morning on Aug 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, rather than being scheduled for later in the afternoon as previously stated. The live stream of the call was broadcast from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts, providing opportunities for questions. No other changes were made to the original release.
Recursion (RXRX) and Exscientia (EXAI) have announced a definitive agreement to merge, creating a global technology-enabled drug discovery leader. The combination aims to leverage Recursion's biology exploration and Exscientia's precision chemistry design capabilities. Key highlights include:
- Expected annual synergies of approximately $100 million
- Combined pipeline with 10 clinical readouts expected in the next 18 months
- Potential for $200 million in milestone payments over 24 months
- Well-capitalized with $850 million in cash and equivalents
- Exscientia shareholders to receive 0.7729 shares of Recursion for each share owned
The merger is expected to close by early 2025, subject to shareholder and regulatory approvals. The combined company will retain the Recursion name and be headquartered in Salt Lake City, Utah.
Recursion (RXRX) announced a definitive agreement to combine with Exscientia, enhancing its drug discovery capabilities. Key highlights include:
1. 7 clinical trial readouts expected for Recursion and 10 collectively with Exscientia over the next 18 months.
2. First neuroscience phenomap optioned by Roche and Genentech, triggering a $30 million payment.
3. Combined deals have potential for over $20 billion in milestones plus royalties.
4. Q2 2024 financial results: Revenue of $14.4 million, up from $11.0 million in Q2 2023. Net loss of $97.5 million, compared to $76.7 million in Q2 2023.
5. Cash position of $474.3 million as of June 30, 2024.
6. Completed a follow-on public offering, raising net proceeds of $216.4 million.
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company, has announced its Q2 2024 financial results and business updates will be released on August 8, 2024, before market open. The company will host a live earnings call at 8:30 am ET / 6:30 am MT on the same day. This event will be streamed live on Recursion's social media platforms including X (formerly Twitter), LinkedIn, and YouTube.
The call is free and open to the public, with a focus on engaging a broad audience and providing opportunities for questions. Interested parties can submit questions in advance through a provided link. This approach demonstrates Recursion's commitment to transparency and shareholder engagement.
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company, has announced it will report its Q2 2024 financial results on Thursday, August 8, 2024, after market close. The company will host a public L(earnings) Call at 5:00 pm ET / 3:00 pm MT on the same day. This event will be live-streamed on Recursion's social media platforms, including X (formerly Twitter), LinkedIn, and YouTube. The call is free and open to the public, with an opportunity for attendees to submit questions. Recursion, known for its work in decoding biology to industrialize drug discovery, encourages participation from those interested in asking questions about the company's business developments.
Recursion Pharmaceuticals (NASDAQ: RXRX), a clinical stage TechBio company, announced the pricing of its public offering of 30,769,230 shares of Class A common stock at $6.50 per share, aiming to raise approximately $200 million. The offering includes a 30-day option for underwriters to purchase an additional 4,615,384 shares. The gross proceeds, before deducting underwriting discounts and commissions, are expected to be $200 million. The offering is set to close around June 28, 2024, pending customary closing conditions. Goldman Sachs and J.P. Morgan are the lead book-running managers. The shares are offered under a registration statement filed with the SEC on May 10, 2022.
Recursion Pharmaceuticals (NASDAQ: RXRX) announced a proposed public offering of $200 million in Class A common stock. The company has also granted underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The offering will be managed by Goldman Sachs & Co. and J.P. Morgan, with Allen & Company also participating. The shares will be offered through a registration statement on Form S-3, effective since May 2022. Completion of the offering is subject to market and other conditions, and there is no assurance on its completion size or terms. Details of the final offering will be disclosed in a final prospectus supplement filed with the SEC.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
